CDKN2A and cancer: In this study, we demonstrated that the cancer cell specificity of ERE73 (1 + 2)-ARF (−13) and ERE73 (3 + 4)-ARF (−13) promoter constructs is significantly greater than that of the native ARF promoter and the commonly used E2F1 and hTERT promoters (Figure 1E).